Newer Positive Inotropic Agents in the Treatment of Chronic Cardiac Failure

Current Status and Future Directions

Karl Weber, Santosh K. Gill, Joseph S. Janicki, Carol S. Maskin, Mukesh C. Jain

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Heart failure is a serious worldwide health problem of major proportions. For many physicians, digitalis (an inotropic agent of limited proportions) and diuretics have proven the standard of treatment for heart failure. Vasodilators have also gained acceptance in recent years. Nevertheless, many patients remain symptomatic and therefore attention has been given to the development of pharmacological agents with mechanisms of action targeted to cardiac and vascular smooth muscle. The newer generation of inotropic agents have clearly been shown to improve the pumping function of the failing heart in patients who remain symptomatic despite digitalis, diuretics and vasodilators, while myocardial oxygen consumption is not enhanced. Several uncontrolled trials with the phosphodiesterase inhibitors enoximone, milrinone and piroximone have concluded that these agents improve exercise capacity and thereby hold promise to enchance quality of life. Large scale controlled trials currently in progress will determine the ultimate efficacy, as well as safety, of these agents. Results to date with several orally active β-adrenoceptor agonists suggest that their efficacy may be limited by the induction of ventricular arrhythmias.

Original languageEnglish (US)
Pages (from-to)503-519
Number of pages17
JournalDrugs
Volume33
Issue number5
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

piroximone
Digitalis
Vasodilator Agents
Diuretics
Enoximone
Heart Failure
Milrinone
Phosphodiesterase Inhibitors
Treatment Failure
Vascular Smooth Muscle
Oxygen Consumption
Adrenergic Receptors
Cardiac Arrhythmias
Quality of Life
Pharmacology
Exercise
Physicians
Safety
Therapeutics
Direction compound

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Newer Positive Inotropic Agents in the Treatment of Chronic Cardiac Failure : Current Status and Future Directions. / Weber, Karl; Gill, Santosh K.; Janicki, Joseph S.; Maskin, Carol S.; Jain, Mukesh C.

In: Drugs, Vol. 33, No. 5, 01.01.1987, p. 503-519.

Research output: Contribution to journalReview article

Weber, Karl ; Gill, Santosh K. ; Janicki, Joseph S. ; Maskin, Carol S. ; Jain, Mukesh C. / Newer Positive Inotropic Agents in the Treatment of Chronic Cardiac Failure : Current Status and Future Directions. In: Drugs. 1987 ; Vol. 33, No. 5. pp. 503-519.
@article{b18582c69f5b4ca0a8fd59be53498bd1,
title = "Newer Positive Inotropic Agents in the Treatment of Chronic Cardiac Failure: Current Status and Future Directions",
abstract = "Heart failure is a serious worldwide health problem of major proportions. For many physicians, digitalis (an inotropic agent of limited proportions) and diuretics have proven the standard of treatment for heart failure. Vasodilators have also gained acceptance in recent years. Nevertheless, many patients remain symptomatic and therefore attention has been given to the development of pharmacological agents with mechanisms of action targeted to cardiac and vascular smooth muscle. The newer generation of inotropic agents have clearly been shown to improve the pumping function of the failing heart in patients who remain symptomatic despite digitalis, diuretics and vasodilators, while myocardial oxygen consumption is not enhanced. Several uncontrolled trials with the phosphodiesterase inhibitors enoximone, milrinone and piroximone have concluded that these agents improve exercise capacity and thereby hold promise to enchance quality of life. Large scale controlled trials currently in progress will determine the ultimate efficacy, as well as safety, of these agents. Results to date with several orally active β-adrenoceptor agonists suggest that their efficacy may be limited by the induction of ventricular arrhythmias.",
author = "Karl Weber and Gill, {Santosh K.} and Janicki, {Joseph S.} and Maskin, {Carol S.} and Jain, {Mukesh C.}",
year = "1987",
month = "1",
day = "1",
doi = "10.2165/00003495-198733050-00005",
language = "English (US)",
volume = "33",
pages = "503--519",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Newer Positive Inotropic Agents in the Treatment of Chronic Cardiac Failure

T2 - Current Status and Future Directions

AU - Weber, Karl

AU - Gill, Santosh K.

AU - Janicki, Joseph S.

AU - Maskin, Carol S.

AU - Jain, Mukesh C.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Heart failure is a serious worldwide health problem of major proportions. For many physicians, digitalis (an inotropic agent of limited proportions) and diuretics have proven the standard of treatment for heart failure. Vasodilators have also gained acceptance in recent years. Nevertheless, many patients remain symptomatic and therefore attention has been given to the development of pharmacological agents with mechanisms of action targeted to cardiac and vascular smooth muscle. The newer generation of inotropic agents have clearly been shown to improve the pumping function of the failing heart in patients who remain symptomatic despite digitalis, diuretics and vasodilators, while myocardial oxygen consumption is not enhanced. Several uncontrolled trials with the phosphodiesterase inhibitors enoximone, milrinone and piroximone have concluded that these agents improve exercise capacity and thereby hold promise to enchance quality of life. Large scale controlled trials currently in progress will determine the ultimate efficacy, as well as safety, of these agents. Results to date with several orally active β-adrenoceptor agonists suggest that their efficacy may be limited by the induction of ventricular arrhythmias.

AB - Heart failure is a serious worldwide health problem of major proportions. For many physicians, digitalis (an inotropic agent of limited proportions) and diuretics have proven the standard of treatment for heart failure. Vasodilators have also gained acceptance in recent years. Nevertheless, many patients remain symptomatic and therefore attention has been given to the development of pharmacological agents with mechanisms of action targeted to cardiac and vascular smooth muscle. The newer generation of inotropic agents have clearly been shown to improve the pumping function of the failing heart in patients who remain symptomatic despite digitalis, diuretics and vasodilators, while myocardial oxygen consumption is not enhanced. Several uncontrolled trials with the phosphodiesterase inhibitors enoximone, milrinone and piroximone have concluded that these agents improve exercise capacity and thereby hold promise to enchance quality of life. Large scale controlled trials currently in progress will determine the ultimate efficacy, as well as safety, of these agents. Results to date with several orally active β-adrenoceptor agonists suggest that their efficacy may be limited by the induction of ventricular arrhythmias.

UR - http://www.scopus.com/inward/record.url?scp=0023213265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023213265&partnerID=8YFLogxK

U2 - 10.2165/00003495-198733050-00005

DO - 10.2165/00003495-198733050-00005

M3 - Review article

VL - 33

SP - 503

EP - 519

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 5

ER -